Argos Therapeutics, Inc. (NASDAQ:ARGS) appreciated by 24.27% at $0.22. Argos Therapeutics, Inc. has 58.62 million shares outstanding, and in the last trade has seen ATR around 0.03. The volume of ARGS witnessed a shift from 67.4 million shares, based on a 50-day average, to 3.54 million shares.

In the most updated research from a number of analysts on Wall Street, the company gets 0 Buys and 0 Sell among 1 analysts. Argos Therapeutics, Inc. (NASDAQ:ARGS) hasconsensus analyst target price is $0. That gives us a street projected return of -100%.

Argos Therapeutics, Inc. most recently reported earnings per share (EPS) of -$0.13 for the June 2017 versus -$0.32 in the same quarter last year, representing -59% growth. Analysts had predicted -$0.2. Revenue during the quarter was $50000, representing -67% growth from $150000 in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as -35% to the downside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

On a similar note, analysts expect EPS in September 2017 quarter and in December 2017 quarter, representing -312288% and -270100% growth, respectively. They expect this year’s earnings to fall -60280.7% year-over-year, followed by 0% decline in the next year.

Shares of Bank of America Corporation (NYSE:BAC) traded down -0.41% in the last session while performance was up 26.4% in the last five days. The stock’s last price was higher from the average trading price of 50 days recorded at $25.84 while enlarging the period to 200 trading days, the average price was $24.32. Currently, 10.42 billion total shares are owned by the public and among those 10.42 billion shares have been available to trade. The percentage of shares being held by the company management was 0.13% while institutional stake was 70.9%.

Bank of America Corporation (BAC) has risen 41.71% since then. But since then, those gains have faded by -5.65%. BAC has risen 2.21% in the 1-month period.

Argos Therapeutics, Inc. has a beta of 1.32, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $1.72 a share in the trailing twelve months. It last reported revenues of $22.08 billion and EPS of $0.48 for the September 2017, representing 1% top-line growth and 0.41 EPS growth.

Looking forward, the company’s quarterly earnings are expected to come at $0.47 in the three months through December 2017 and $0.44 in the quarter ending March 2018, reflecting 17.5% and 7.32% growth, respectively. For the full year, analysts expect earnings to jump 20% yoy to $1.8. Next year this growth will reach 18.33% to attain $2.13.